NASDAQ:KYTX Kyverna Therapeutics (KYTX) Stock Price, News & Analysis $7.96 +0.21 (+2.71%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$8.02 +0.06 (+0.75%) As of 08/7/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kyverna Therapeutics Stock (NASDAQ:KYTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kyverna Therapeutics alerts:Sign Up Key Stats Today's Range$7.76▼$8.1350-Day Range$7.07▼$9.9152-Week Range$2.80▼$13.67Volume431,396 shsAverage Volume1.02 million shsMarket Capitalization$483.89 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingModerate Buy Company Overview Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression. The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions. Kyverna’s approach centers on scalable manufacturing processes and precision cell engineering, enabling the production of off‐the‐shelf therapeutic products with defined dosing and predictable pharmacology. Collaborations with academic institutions and biotech partners support its pipeline advancement and translational research efforts. Founded in 2021 and headquartered in Cambridge, Massachusetts, Kyverna Therapeutics draws on a leadership team with deep expertise in cell therapy, immunology and bioprocess development. The company operates research and manufacturing facilities in the Greater Boston area and engages with regulatory authorities in North America and Europe to advance its clinical programs. Kyverna’s strategic vision is to pioneer durable, disease‐modifying treatments that address high‐unmet needs in autoimmune and inflammatory disorders.AI Generated. May Contain Errors. Read More Kyverna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreKYTX MarketRank™: Kyverna Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 719th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingKyverna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialKyverna Therapeutics has a consensus price target of $30.00, representing about 276.9% upside from its current price of $7.96.Amount of Analyst CoverageKyverna Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Kyverna Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kyverna Therapeutics are expected to grow in the coming year, from ($2.78) to ($2.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kyverna Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kyverna Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKyverna Therapeutics has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Kyverna Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.66% of the float of Kyverna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKyverna Therapeutics has a short interest ratio ("days to cover") of 6.05.Change versus previous monthShort interest in Kyverna Therapeutics has recently increased by 8.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKyverna Therapeutics does not currently pay a dividend.Dividend GrowthKyverna Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Kyverna Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for KYTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.60% of the stock of Kyverna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions18.08% of the stock of Kyverna Therapeutics is held by institutions.Read more about Kyverna Therapeutics' insider trading history. Receive KYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYTX Stock News HeadlinesKyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program AdvancementJuly 29, 2026 | seekingalpha.comKyverna secures long-term miv-cel manufacturing partnershipJuly 27, 2026 | tipranks.comBeijing's gold number doesn't add upGoldman Sachs ran the physical gold flows through the London market and found China's real reserves could be 4.8 times the official figure Beijing reports. China's central bank has now bought gold for 20 straight months, its longest streak in at least a decade, even as gold just posted its worst quarterly drop in 13 years. Washington has already responded. On May 21, 2026, a federal bank board unanimously approved a nearly 3 billion dollar loan to build a gold mine on American soil.August 8 at 1:00 AM | Behind the Markets (Ad)Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-celJuly 27, 2026 | globenewswire.comKyverna’s KYSA-8 Trial Completion Puts Autoimmune Cell Therapy in Investor FocusJuly 25, 2026 | theglobeandmail.comKyverna Therapeutics Sinks 13%: Here's WhyJuly 10, 2026 | 247wallst.comKyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and BeyondJuly 9, 2026 | finance.yahoo.comKyverna Therapeutics Amends Term Loan, Extends Capital AccessJuly 9, 2026 | tipranks.comSee More Headlines KYTX Stock Analysis - Frequently Asked Questions How have KYTX shares performed this year? Kyverna Therapeutics' stock was trading at $9.40 at the beginning of the year. Since then, KYTX stock has decreased by 15.3% and is now trading at $7.96. How were Kyverna Therapeutics' earnings last quarter? Kyverna Therapeutics, Inc. (NASDAQ:KYTX) issued its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.09. When did Kyverna Therapeutics IPO? Kyverna Therapeutics (KYTX) raised $297 million in an initial public offering on Thursday, February 8th 2024. The company issued 14,500,000 shares at a price of $20.00-$21.00 per share. Who are Kyverna Therapeutics' major shareholders? Kyverna Therapeutics' top institutional investors include BlackRock Inc. (5.16%), AIGH Capital Management LLC (4.60%), Walleye Capital LLC (0.40%) and Bank of New York Mellon Corp (0.16%). Insiders that own company stock include Biopartners Opportuni Westlake, Beth C Seidenberg, Northpond Ventures Iii Gp, Llc and Karen Marie Walker. View institutional ownership trends. How do I buy shares of Kyverna Therapeutics? Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kyverna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/12/2026Today8/08/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 KYTX's financial health is in the Green zone, according to TradeSmith. KYTX has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KYTX Previous SymbolNASDAQ:KYTX CIK1994702 Webkyvernatx.com Phone510-626-8331FaxN/AEmployees96Year Founded2018Price Target and Rating Average Price Target for Kyverna Therapeutics$30.00 High Price Target$33.00 Low Price Target$25.00 Potential Upside/Downside+276.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$161.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-81.88% Return on Assets-64.87% Debt Debt-to-Equity Ratio0.13 Current Ratio8.15 Quick Ratio8.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.85 per share Price / Book2.07Miscellaneous Outstanding Shares60,790,000Free Float50,095,000Market Cap$483.89 million OptionableOptionable Beta1.93 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:KYTX) was last updated on 8/8/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredA $5 stock inside Kennedy Space Center?A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredSpaceX Earnings Crash: The End of the AI Bubble?Jeremy Grantham calls today's market the biggest investment bubble in American history, and Ray Dalio agrees. ...TradeSmith | SponsoredBeginner’s Guide to GoldThe Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...Goldco Direct, LLC | SponsoredWhy Trump really wants GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then,...Porter & Company | SponsoredWhat Elon told his top shareholders in TexasLate last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
